Japan Approves World-First iPS Stem-Cell Therapy for Parkinson’s Disease

The regulatory approval of the world’s first induced pluripotent stem cell (iPS) treatment for Parkinson’s disease in Japan represents a watershed moment for regenerative medicine. This decision by the Ministry of Health, Labour and Welfare (MHLW) validates over two decades of research led by Nobel laureate Shinya Yamanaka and his team at Kyoto University’s Center for iPS Cell Research and Application (CiRA). By clearing this therapy for clinical use, Japan has effectively established itself as the global leader in the commercialization of advanced cellular therapies, outpacing both the United States and the European Union in the race to bring iPS-based treatments to market.

Parkinson’s disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, leading to debilitating motor symptoms such as tremors, rigidity, and bradykinesia. While current standards of care, such as Levodopa, manage symptoms by supplementing dopamine levels, they do not halt the underlying neurodegeneration. The newly approved therapy takes a fundamentally different approach: it involves the transplantation of approximately 5 million iPS-derived dopaminergic progenitor cells into the patient's putamen. These cells are designed to integrate into the brain tissue and function as a long-term, biological source of dopamine, potentially offering a functional cure or significantly reducing the need for daily medication.

“

This decision by the Ministry of Health, Labour and Welfare (MHLW) validates over two decades of research led by Nobel laureate Shinya Yamanaka and his team at Kyoto University’s Center for iPS Cell Research and Application (CiRA).

The approval follows a rigorous clinical trial phase that began in 2018 at Kyoto University Hospital. During these trials, seven patients with moderate Parkinson’s disease underwent the procedure, which involved a specialized surgical device to inject the cells. Data from the two-year follow-up period indicated that the treatment was not only safe—showing no signs of tumor formation or immune rejection—but also effective in improving motor function. This success is particularly notable given the historical challenges of stem cell therapy, including the risk of tumorigenicity and the complexities of ensuring cell survival post-transplantation.